Related references
Note: Only part of the references are listed.Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
Shannon Burke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Michael D. Oberst et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy (vol 128, pg 1413, 2018)
Dmitriy Zamarin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment
Nam Hee Lee et al.
ONCOTARGET (2017)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Nicholas M. Durham et al.
MOLECULAR THERAPY (2017)
Interferon Gamma induces changes in Natural Killer (NK)Cell Ligand Expression and Alter NK Cell-Mediated and Alters NK Cell-Mediated Lysis of pediatric Cancer Cell Lines
Arianexys Aquino-Lopez et al.
FRONTIERS IN IMMUNOLOGY (2017)
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland et al.
CLINICAL CANCER RESEARCH (2017)
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
Xing Cheng et al.
JOURNAL OF VIROLOGY (2016)
Oncolytic Viruses: Therapeutics With an Identity Crisis
Caroline J. Breitbach et al.
EBIOMEDICINE (2016)
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
A. Wang et al.
EJSO (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Fu et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Jasper G. van den Boorn et al.
IMMUNITY (2013)
Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells
Yan Zhang et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2012)
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
Dmitriy Zamarin et al.
FUTURE MICROBIOLOGY (2012)
Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion
Soren Jensen et al.
JOURNAL OF VIROLOGY (2012)
Oncolytic Virotherapy for Hematological Malignancies
Swarna Bais et al.
ADVANCES IN VIROLOGY (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
Robert M. Lorence et al.
CURRENT CANCER DRUG TARGETS (2007)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Share Paper
